After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The FDA throws out the company’s second attempt at an accelerated approval.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
